Researchers studying bladder cancer at the NYUCI are focusing on the following areas of study:
Molecular Basis Underlying the Divergent Pathways of Bladder Tumorigenesis
NYUCI scientists are exploring the roles of tumor suppressor genes (Rb family, p53, Ink4a, and PTEN) in bladder tumorigenesis and progression. They are also studying DNA repair capacity in the etiology of bladder cancer, the roles of XIAP and RhoGDI in bladder cancer invasion and metastasis, and the structural basis of FGFR3 activation. The findings of these studies could help investigators identify new therapeutic targets.
New Diagnostic Markers for Bladder Cancer
Researchers are conducting studies of the usefulness of uroplakins to improve bladder cancer diagnosis and management.
Novel Therapeutic Strategies for Bladder Cancer
Several avenues of investigation are under way, including those assessing:
- The effects of a novel hydroxamate-type HDAC inhibitor, PDX101, on bladder tumor growth in transgenic mice.
- Rational targeting of the FGF3 receptor in bladder cancer
- Oncolytic herpes simplex virus (HSV) virus therapy in bladder cancer
Urothelial Differentiation and Implications on Bladder Cancer
NYUCI scientists are evaluating cultured urothelial cells as a model of urothelial wound repair. They are also exploring the roles of uroplakins in plaque formation, umbrella cell enlargement, and urinary tract diseases, as well as the mechanism of uroplakin assembly and novel urothelial markers.